FDA approval summary, phase 3 trial of 1,063 patients with muscle-invasive bladder cancer: adding perioperative durvalumab to neoadjuvant gemcitabine–cisplatin improved event-free survival at interim analysis (HR 0.68) and OS (HR 0.75); pCR did not differ.
RCTn = 1,063 patients
Mirkheshti et al. FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer